Clinical trials
1 active trial in Brazil, Mexico, Ecuador and Haiti
Recruiting, about to start, or running now. Counted across the 4 countries we report on in Latin America.
See every trial on ClinicalTrials.gov (opens in a new tab)
Updated
Reviewed by Vidhi Upadhyay
Latin America Insulin Biosimilars Market Industry Trends and Forecast to 2034: Segmented by (Type, Delivery, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$506.6 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $183.5 Mn | — | — |
| 2025 (base) | $210.3 Mn | +$26.8 Mn | — |
| 2026 (forecast) | $241.0 Mn | +$30.7 Mn | +14.6% |
| 2027 (forecast) | $276.1 Mn | +$35.2 Mn | +31.3% |
| 2028 (forecast) | $316.5 Mn | +$40.3 Mn | +50.5% |
| 2029 (forecast) | $362.7 Mn | +$46.2 Mn | +72.5% |
| 2030 (forecast) | $415.6 Mn | +$52.9 Mn | +97.7% |
| 2031 (forecast) | $476.3 Mn | +$60.7 Mn | +126.5% |
| 2032 (forecast) | $545.8 Mn | +$69.5 Mn | +159.6% |
| 2033 (forecast) | $625.5 Mn | +$79.7 Mn | +197.5% |
| 2034 (forecast) | $716.8 Mn | +$91.3 Mn | +240.9% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $210.3 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $716.8 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 14.6% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Type, delivery and end user (see all) |
| Key players | Biocon, Viatris, Sanofi, Eli Lilly and Company, Gan & Lee Pharmaceuticals and 1 more (see all) |
| Active clinical trials | 1 in Latin AmericaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Latin America. Retrieved 12 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Insulin biosimilars are lower-cost versions of branded insulins that work the same way, improving access to diabetes treatment.
Key segments of the insulin Biosimilars market include type (Long-Acting, Rapid-Acting and Premixed) and delivery (Vials, Pens and Cartridges).
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the insulin Biosimilars market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the insulin Biosimilars market, especially in fast-growing emerging economies.
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the insulin Biosimilars market. Long-term safety data and lifestyle support are still needed for many patients.
The insulin Biosimilars market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medicines are approved by ANVISA (Brazil)[1], ARCSA (Ecuador)[2] and COFEPRIS (Mexico)[3]. How care is paid for in some of these countries: the SUS (Brazil)[4]; public care and IESS (Ecuador)[5]; and IMSS, ISSSTE and IMSS-Bienestar (Mexico)[6]. ClinicalTrials.gov lists 1 study on Insulin Biosimilars that is recruiting, active or about to start in Latin America.[7]
[1] ANVISA. Checked 14 Nov 2026.
[2] ARCSA. Checked 14 Nov 2026.
[3] COFEPRIS. Checked 14 Nov 2026.
[4] CONITEC. Checked 14 Nov 2026.
[5] Ministry of Public Health of Ecuador. Checked 14 Nov 2026.
[6] Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.
[7] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Latin America. Retrieved 12 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for insulin Biosimilars. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Latin America.
What doctors and scientists are doing in Insulin Biosimilars right now, from free public sources.
1 active trial in Brazil, Mexico, Ecuador and Haiti
Recruiting, about to start, or running now. Counted across the 4 countries we report on in Latin America.
See every trial on ClinicalTrials.gov (opens in a new tab)| Country | Value | Year |
|---|---|---|
| Brazil | 12.9 | 2022 |
| Ecuador | 12.7 | 2022 |
| Haiti | 23.7 | 2022 |
| Mexico | 14.3 | 2022 |
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Latin America
Latin America
Latin America
Latin America
Latin America
Latin America
Medical Devices · Latin America
Medical Devices · Latin America
Medical Devices · Latin America
Healthcare Services · Latin America
Healthcare Services · Latin America
Healthcare Services · Latin America